Clinical Trials

Last Updated: 02/10/2017

Marginal zone lymphoma, small lymphocytic leukemia

Previously Treated

2015-1132 (Ka2237):  Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Ka2237 in Patients with B Cell Lymphoma2015-0918 (M

2015-0918 (MT3724): Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects with Refractory Non-Hodgkin Lymphoma (NHL)

2015-0811 (MT3724): Extended Treatment Access Study of MT-3724 for Subjects with Relapsed non-Hodgkin’s B-Cell Lymphoma Who Have Completed Phase I/Ib Study MT-3724_NHL_001_US

2013-0261 (Len+ Obinutuzumab):  Phase I/II study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin’s Lymphoma

Follicular lymphoma

Newly Diagnosed

2015-0361 (ibrutinib + rituximab/lenalidomide): Open label, phase 2 study of ibrutinib in combination with rituximab and lenalidomide in previously untreated subjects with follicular lymphoma

2015-0464 (obinutuzmab + lenalidomide): An Open Label, Phase 2 study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects with Follicular Lymphoma

Previously Treated

2015-1132 (Ka2237):  Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Ka2237 in Patients with B Cell Lymphoma

2015-0811 (MT3724): Extended Treatment Access Study of MT-3724 for Subjects with Relapsed non-Hodgkin’s B-Cell Lymphoma Who Have Completed Phase I/Ib Study MT-3724_NHL_001_US

2015-0663 (BGB-3111):  Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with B-Cell Lymphoid Malignancies

2015-0160 (ADCT-301): Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

2015-0038 (Rituximab + Lenalidomide  vs  Rituximab + placebo): Phase 3, Double-blind Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013 Versus Rituximab Plus Placebo in Subjects with Relapsed/Refractory Indolent Lymphoma

2014-0539 (ACP-196): Phase II study of rituximab plus pembrolizumab (MK-3475) in subjects with relapsed follicular lymphoma

2012-0602 (MLN8237 + Romidepsin):  Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas

2015-1063 (Anti-PD-L1 Antibody): A Phase 1/2 Open label Multicenter study to assess the safety and tolerability of Durvalumab (Anti-PD-L1 Antibody) as Monotherapy and in combination therapy in subjects with lymphoma or chronic lymphocytic leukemia

2016-0586 (CC-122, CC-223, CC-292): A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292 and Rituximab in Diffuse Large B-Cell Lymphoma

2015-0668 (JNJ-64052781): A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64052781, a Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects with Relapsed or Refractory B-cell Malignancies

2015-0417 (ASN002): A Phase 1/2, Open-Label, Uncontrolled, Multipledose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors 

Diffuse large B-cell lymphoma

Newly Diagnosed 

2015-0147 (Ritux /Lenalid / Ibrutinib + Chemo): Phase I/II Study of Lenalidomide and Obinutuzumab with CHOP for Diffuse Large B Cell Lymphoma

2015-0069 (Lenalidomide + Obinutuzumab + CHOP): Phase I/II Study of Lenalidomide and Obinutuzumab with CHOP for Diffuse Large B-Cell Lymphoma

 Previously Treated 

2016-0574 (KTE-C19 + Atezolizumab): Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination with Atezolizumab in Subjects with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

2016-0035 ( CUDC-907): Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations

2015-0567 (CTL019): Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

2015-0022: Pilot Project for Creation of the DLBCL Response Prediction Model: Combining Early Interim Functional Imaging, Detection Of A Tumor-Specific Clonotype and Metabolic Profiling of Blood Of In Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma To Predict Response To Standard Immunochemotherapy

2014-1072 (ACP-196 + Pembrolizumab): Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects with B-cell Malignancies

2014-0815 (KTE-C19): Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

2014-0703 ( KPT-330 + Dexamethasone): Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

2012-0602 (MLN8237 + Romidepsin):  Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas

2015-0993 (SGN-CD19A):A randomized, open-label phase 2 study of denintuzumab mafodotin (SGN-CD19A) plus rituximab, ifosfamide, carboplatin, and etoposide (19A+RICE) chemotherapy vs. RICE in the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are candidates for autologous stem cell transplant

2015-0916 (MK-3475): A Phase II Study of Pembrolizumab (MK-3475) in Subjects with Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

2015-0668 (JNJ-64052781): A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64052781, a Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects with Relapsed or Refractory B-cell Malignancies

2015-0417 (ASN002): A Phase 1/2, Open-Label, Uncontrolled, Multipledose Escalation, Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ASN002 in Relapsed/Refractory Lymphoma and Advanced Solid Tumors 

2015-1101 (MEDI4736): A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma

2014-0501 (TAK-228): Phase II study of TAK-228 in Relapsed Lymphoma with the goals of this clinical research study are to find the highest tolerable dose of TAK228 that can be given to patients with relapsed lymphoma, and then to learn if TAK228 can help to control the disease

Hodgkin's lymphoma

Prior Treated

2016-0184 ( Pembrolizumab vs. Brentuximab Vedotin): Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma

2015-0160 (ADCT-301): Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

2012-0602 (MLN8237 + Romidepsin):  Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas

2016-0423 (ABVD): Phase II, Multi-center Trial of Nivolumab and Brentuximab Vedotin in Patients with Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) Chemotherapy

Mantle cell lymphoma 

Newly Diagnosed

2016-0024 (ACP-196): Phase 1b, Multicenter, Open-label Study of ACP-196 in Combination with Bendamustine and Rituximab (BR) in Subjects with Mantle Cell Lymphoma

2014-0559 (Ibrutinib + Rituximab/Hyper-CVAD): Phase II Study of Ibrutinib plus Rituximab with Hyper-CVAD Consolidation in Newly Diagnosed Young Patients with Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy before Chemotherapy

2013-0090 (Ibrutinib + Rituximab): Phase II Study of Ibrutinib Plus Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients with Newly Diagnosed MCL

Previously Treated

2015-0862 (idealsib): Phase Ib dose escalation study of BCL201 in combination with idelalisib in patients with Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)

2015-0811 (MT3724): Extended Treatment Access Study of MT-3724 for Subjects with Relapsed non-Hodgkin’s B-Cell Lymphoma Who Have Completed Phase I/Ib Study MT-3724_NHL_001_US

2015-0663 (BGB-3111): Phase I, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects with B-Cell Lymphoid Malignancies

2015-0529 (CAR T-cells): Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)

2015-0372 (KTE-C19): Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

2015-0160 (ADCT-301): Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

2014-0630 (Akt and ERK inhibitor): Phase I/II Study of Oral ONC201 in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma

2012-1107 (2010-0837) (PCI-32765):Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study

2012-0602 (MLN8237 + Romidepsin):  Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell Lymphomas

2013-0677 (PCI-32765 + BTK inhibitor): A Phase I/II Trial of PCI-32765 (BTK inhibitor) in Combination with Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

2013-0259 (Carfilzomib): A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

2012-0188 (Carfilzomib + Lenalidomide/Rituximab): A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Burkitt's Lymphoma

Newly Diagnosed

2009-0833 (Rituximab, Dose Adjusted EPOCH): Phase 2 Study of Dose-Adjusted Epoch+/- Rituximab in Adults with Untreated Burkitt's Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma.

Previously Treated 

2015-0811 (MT3724): Extended Treatment Access Study of MT-3724 for Subjects with Relapsed non-Hodgkin’s B-Cell Lymphoma Who Have Completed Phase I/Ib Study MT-3724_NHL_001_US

2015-0160 (ADCT-301): Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

2012-0602 (MLN8237 + Romidepsin):  Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell 

2014-0504  (MT-324): Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of
MT-3724 for the Treatment of Patients with Relapsed non-Hodgkin’s B-Cell Lymphoma 

2014-0324 (TGR-1202):  A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Novel PI3k Delta Inhibitor, in Patients with B-cell Malignancies 

Peripheral T-Cell Lymphoma

Newly Diagnosed

2015-0555 (Folotyn®): Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)

2012-0630 (Brentuximab, CHP): Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-Cell lymphomas.  

2013-0367 Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients with Stage I/II Nasal NK Cell Lymphoma

Previously Treated

2016-0034 (MK-3475): Phase II study to determine feasibility and safety of single agent MK-3475 in relapsed or refractory Peripheral T-cell Non-Hodgkin lymphoma

2015-0555 (Folotyn + CHOP): Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)Phase I

2015-0367 (Chemo + Radiation):  Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients with Stage I/II Nasal NK Cell Lymphoma

2015-0160 (ADCT-301): Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma

2015-0130 (RP6530): Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a dual PI3K delta/gamma inhibitor, in Patients with Relapsed or Refractory T-cell Lymphoma

2013-0915 (EBV-Specific T cells):  Phase 2 Open Label Study to Investigate the Efficacy of Autologous EBV-Specific T Cell for the Treatment of Patients with Aggressive Extranodal NK/T Cell Lymphoma (ENKTCL)

2012-0602 (MLN8237 + Romidepsin):  Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-cell and T-cell 

 

Amyloidosis

Newly Diagnosed

2015-0554 (NEOD001): A Phase 3, Randomized, Multicenter, Double-Blind,Placebo- Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

Previously Treated

2015-1057 (NEOD001): Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects with Light Chain (AL) Amyloidosis who have Persistent Cardiac Dysfunction

Waldenstrom’s

Asymptomatic

2009-0465 (Vaccine ): Phase I Study of an Active Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma with DNA Vaccines Encoding Antigen-Chemokine Fusion   

Previously Treated

2013-0951 (IMO-8400):  Phase 1/2 Open-Label, Multiple-Dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Waldenstrom’s Macroglobulinemia

Myeloma

Newly Diagnosed 

Symptomatic/Patients Not Eligible for Transplant

2015-0019 (Daratumumab): Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs. Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy

2015-0148 (SAR650984): Phase II single arm trial of SAR650984 in patients with intermediate and high risk smoldering multiple myeloma

Asymptomatic Myeloma

2015-0371 (Pembroluzomab): Pilot single arm, single center, open label trial of pembrolizumab in patients with intermediate and high risk smoldering multiple myeloma

Previously Treated

2015-1037 (Pomalidomide + dexamethasone w/wo pembroluzomab): Phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK-3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM)

2013-0950 (MK-3475 with Len/Dex): Phase 1 Trial of MK-3475 (pembrolizumab) in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

2012-1159 (SCH 727965, Bortezomib, Dexamethasone): Phase 1 Clinical Trial of a Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination with Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

Novel Therapies 

2015-1039 (AMG 224): Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects with Relapsed or Refractory Multiple Myeloma

2015-0101 (DS-3032b):  Phase I Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects with Relapsed and/or Refractory Multiple Myeloma

2014-0742 (CWP232291 +/- lenalidomide/dexamethasone): A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety,  Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination with Lenalidomide and Dexamethasone in Subjects with Relapsed or Refractory Myeloma

2013-0018 (Pom/Dex + G-CFS): Phase 1/2 Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma

Maintenance therapy after stem cell transplant

2014-0729 (Elotuzumab + Lenalidomide):  Phase II Study of the combination of Elotuzumab with Lenalidomide as Maintenance Therapy post Autologous Stem Cell Transplant in Patients with Multiple Myeloma